In particular, high VEGF-A expression positively correlated with stages II-IV or with reduced survival in Finish CRC patients5; while, bevacizumab, a recombinant humanized monoclonal antibody against VEGF-A, improved patient survival6. The gene discussed is VEGFA; the disease is colorectal carcinoma.